Circulating Tumor Cells in Peripheral Blood As a Diagnostic Biomarker of Breast Cancer: A Meta-analysis

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 Apr 10

PMID 37035139

Authors

Tao Jin

Yao Chen

Qing-Yan Chen

Yang Xiong

Ji-Qiao Yang

Affiliations

Soon will be listed here.

Abstract

Purpose: Studies have reported that breast cancer (BC) patients' circulating tumor cells (CTCs) have varying results for their diagnostic role. Thus, we conducted a meta-analysis to systematically assess the accuracy of CTCs in the diagnosis of BC.

Methods: A meta-analysis was conducted to evaluate the overall accuracy of CTC detection. A pooled analysis of sensitivity (SEN), specificity (SPE), positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic advantage ratio (DOR) was used to measure diagnostic accuracy. In addition, the area under the summary receiver operating characteristic curve (AUC) was used to discriminate BC from non-BC. An analysis of the threshold effect was calculated using the Spearman correlation coefficient. We calculated the Q and I2 statistics to determine whether the studies were heterogeneous. Sensitivity analysis was performed by removing studies one by one. Publication bias was assessed by Deeks' funnel plot asymmetry test.

Results: Studies from the PubMed, Cochrane Library, Embase, Web of Science, Wanfang, Vip, and CNKI databases were collected for diagnosing BC from January 2000 to April March 2023. Finally, 8 publications were retrieved in total containing 2014 cases involved in the study. Based on a random-effects model, it was found that the pooled SEN was 0.69 (0.55 - 0.80), SPE was 0.93 (0.60 - 0.99), PLR was 9.5 (1.4 - 65.9), NLR was 0.33 (0.23 - 0.48), DOR was 29 (4 - 205) and the AUC of the summary receiver operating characteristic (SROC) curve was 0.81 (0.77 - 0.84). Some heterogeneity was found in the article, but there was no threshold effect to account for it (P = 0.27). Deek's funnel plot asymmetry test indicated that no publication bias was observed in this meta-analysis (P = 0.52).

Conclusion: The results of this meta-analysis confirmed that CTCs were an important component of noninvasive methods of confirming BC with SEN of 0.69 (0.55 - 0.80), SPE of 0.93 (0.60 - 0.99) and AUC of 0.81 (0.77 - 0.84).

Citing Articles

A revolutionary era in advancing precision immuno-oncology; role of circulating tumor cells.

Bahmaie N, Ozensoy Guler O, Simsek E J Liq Biopsy. 2025; 6:100169.

PMID: 40027303 PMC: 11863822. DOI: 10.1016/j.jlb.2024.100169.

Characterization of EpCAM-Positive and EpCAM-Negative Tumor Cells in Early-Stage Breast Cancer.

Perelmuter V, Grigoryeva E, Alifanov V, Kalinchuk A, Andryuhova E, Savelieva O Int J Mol Sci. 2024; 25(20).

PMID: 39456890 PMC: 11508537. DOI: 10.3390/ijms252011109.

References

Murray N, Miranda R, Ruiz A, Droguett E . Diagnostic yield of primary circulating tumor cells in women suspected of breast cancer: the BEST (Breast Early Screening Test) study. Asian Pac J Cancer Prev. 2015; 16(5):1929-34. DOI: 10.7314/apjcp.2015.16.5.1929. View

Krawczyk N, Banys M, Hartkopf A, Hagenbeck C, Melcher C, Fehm T . Circulating tumour cells in breast cancer. Ecancermedicalscience. 2013; 7:352. PMC: 3776645. DOI: 10.3332/ecancer.2013.352. View

Maly V, Maly O, Kolostova K, Bobek V . Circulating Tumor Cells in Diagnosis and Treatment of Lung Cancer. In Vivo. 2019; 33(4):1027-1037. PMC: 6689346. DOI: 10.21873/invivo.11571. View

Brooks M . Breast cancer screening and biomarkers. Methods Mol Biol. 2008; 472:307-21. DOI: 10.1007/978-1-60327-492-0_13. View

Gradishar W, Anderson B, Balassanian R, Blair S, Burstein H, Cyr A . Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018; 16(3):310-320. DOI: 10.6004/jnccn.2018.0012. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1):7-34. DOI: 10.3322/caac.21551. View

Chang Y, Min J, Jarusiewicz J, Actis M, Yu-Chen Bradford S, Mayasundari A . Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia. Blood. 2021; 138(23):2313-2326. PMC: 8662068. DOI: 10.1182/blood.2020006846. View

Chu W, Ryu D . Clinical significance of serum CA15-3 as a prognostic parameter during follow-up periods in patients with breast cancer. Ann Surg Treat Res. 2016; 90(2):57-63. PMC: 4751146. DOI: 10.4174/astr.2016.90.2.57. View

Gao Y, Fan W, Duan C, Zhao W, Zhang J, Kang X . Enhancing the Screening Efficiency of Breast Cancer by Combining Conventional Medical Imaging Examinations With Circulating Tumor Cells. Front Oncol. 2021; 11:643003. PMC: 8170472. DOI: 10.3389/fonc.2021.643003. View

10.

Wu S, He Z, Zhou J, Sun J, Li F, Lin Q . Serum levels of CEA and CA15-3 in different molecular subtypes and prognostic value in Chinese breast cancer. Breast. 2013; 23(1):88-93. DOI: 10.1016/j.breast.2013.11.003. View

11.

Jin L, Zhao W, Zhang J, Chen W, Xie T, Wang L . Evaluation of the diagnostic value of circulating tumor cells with CytoSorter CTC capture system in patients with breast cancer. Cancer Med. 2020; 9(5):1638-1647. PMC: 7050089. DOI: 10.1002/cam4.2825. View

12.

Xie N, Hu Z, Tian C, Xiao H, Liu L, Yang X . In Vivo Detection of CTC and CTC Plakoglobin Status Helps Predict Prognosis in Patients with Metastatic Breast Cancer. Pathol Oncol Res. 2020; 26(4):2435-2442. DOI: 10.1007/s12253-020-00847-7. View

13.

Giordano A, Giuliano M, De Laurentiis M, Arpino G, Jackson S, Handy B . Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Ann Oncol. 2011; 23(5):1144-1150. DOI: 10.1093/annonc/mdr434. View

14.

Eroglu Z, Fielder O, Somlo G . Analysis of circulating tumor cells in breast cancer. J Natl Compr Canc Netw. 2013; 11(8):977-85. PMC: 4159355. DOI: 10.6004/jnccn.2013.0118. View

15.

Oeffinger K, Fontham E, Etzioni R, Herzig A, Michaelson J, Shih Y . Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society. JAMA. 2015; 314(15):1599-614. PMC: 4831582. DOI: 10.1001/jama.2015.12783. View

16.

Daly A, Rolph R, Cutress R, Copson E . A Review of Modifiable Risk Factors in Young Women for the Prevention of Breast Cancer. Breast Cancer (Dove Med Press). 2021; 13:241-257. PMC: 8053601. DOI: 10.2147/BCTT.S268401. View

17.

Zhao S, Gai X, Wang Y, Liang W, Gao H, Zhang K . Diagnostic Values of Carcinoembryonic Antigen, Cancer Antigen 15-3 and Cancer Antigen 125 Levels in Nipple Discharge. Chin J Physiol. 2016; 58(6):385-92. DOI: 10.4077/CJP.2015.BAD336. View

18.

Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009; 339:b2700. PMC: 2714672. DOI: 10.1136/bmj.b2700. View

19.

Gao J, Zhang Q, Xu J, Guo L, Li X . Clinical significance of serum miR-21 in breast cancer compared with CA153 and CEA. Chin J Cancer Res. 2014; 25(6):743-8. PMC: 3872537. DOI: 10.3978/j.issn.1000-9604.2013.12.04. View

20.

Zhong X, Zhang H, Zhu Y, Liang Y, Yuan Z, Li J . Circulating tumor cells in cancer patients: developments and clinical applications for immunotherapy. Mol Cancer. 2020; 19(1):15. PMC: 6982393. DOI: 10.1186/s12943-020-1141-9. View